Otsuka America Pharmaceutical Inc.

Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, supplies Jynarque (tolvaptan) and related specialty medications to the Department of Veterans Affairs as a prime contractor on full-and-open federal supply schedule delivery orders, with no subcontract footprint and no SBA set-aside certifications. The company operates entirely as a prime on the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), competing without set-aside designation and drawing task orders from multiple VA regional networks.

Otsuka's federal footprint centers on a single specialty pharmaceutical—Jynarque (tolvaptan), a treatment for autosomal dominant polycystic kidney disease and hyponatremia—distributed across the VA healthcare system. The company holds a single-award Blanket Purchase Agreement with the VA's National Acquisition Center, awarded March 27, 2025, valued at $83.342 billion with completion through March 26, 2027. Under this BPA and the parent GSA schedule, Otsuka has received 240 delivery orders since at least 2021, ranging from roughly $10 thousand to $362.7 million per order. Representative recent awards include a $637.7 million delivery order from Veterans Integrated Service Network 20 for Jynarque bulk supply (October 2024, completion September 2025); a $284.7 million delivery order from VISN 22 for Jynarque (July 2023, completion June 2024); and a $180.9 million sole-source delivery order from VISN 22 through AllianceRx Walgreens Specialty Pharmacy (October 2022, completion September 2023).

Customer concentration is heavily skewed toward the VA system. The top five customer organizations—all VA regional integrated service networks or the National Acquisition Center—account for 85 percent of recent awards by count. However, the dollars concentration diverges sharply: VISN 12 anchors 96 percent of combined potential value across its 16 awards ($400.6 million), while the National Acquisition Center holds 3 awards worth $105.8 million combined. By contrast, VISN 5 (88 awards), VISN 6 (55 awards), and VISN 21 (31 awards) collectively represent the highest volume but carry only $3.2 million in combined potential value, reflecting the routine small-dollar delivery-order structure for direct patient medication supply. This pattern reveals two distinct purchasing postures: large, lumpy annual or multi-year agreements funneled through VISN 12 and NAC, and granular weekly or monthly distribution orders across individual regional networks.

Otsuka's activity trajectory shows steady growth through 2024 (33 awards in 2022, 37 in 2023, 41 in 2024), with a sharp drop in 2025–2026 (10 awards in 2025, 1 in 2026). This collapse reflects the transition to the renewed BPA effective March 27, 2025, which consolidates prior ordering vehicles and resets the task-order stream. The prior BPA ceiling of $83.3 million (awarded before 2025, based on repeated references in legacy award descriptions) has been superseded by the new vehicle with the same vendor at $83.342 billion ceiling through March 2027.

Otsuka competes entirely full-and-open on the GSA schedule with no minority, women-owned, HUBZone, or disadvantaged-business certifications noted. The vendor is not a sub-contractor; all 241 awards in the source are prime awards. The company's business model is essentially a sole-source pharmaceutical manufacturer for a niche indication within the VA, sustained by indefinite delivery vehicles that streamline procurement across dispersed regional networks.